Patellofemoral joint (PFJ) degeneration has been found not to affect outcome following medial unicompartmental knee arthroplasty (UKA). However, PFJ disease occasionally presents as isolated trochlear cartilage lesions, with little available evidence regarding treatment options or necessity. We evaluated the effectiveness of concomitant trochlear resurfacing in patients undergoing medial UKA with asymptomatic trochlear lesions.
We included 60 patients undergoing medial UKA with an associated full thickness lesion of the trochlea. A fixed bearing UKA implant (PKR™, Stryker, Warsaw, IND) was used in all cases. In 30 patients, trochlear lesions were resurfaced with a HemiCAP® PF Classic (HemiCAP® PFC) implant (Arthrosurface, Franklin, MA). Outcome measures included VAS-, KOOS-, WOMAC-, SF-36 scores and radiological assessment.
Average length of follow-up was 97.4 months (range: 88-106 months). Both groups showed significant improvement for all clinical scores post-operatively compared to pre-operatively (p < 0.001 for all). The UKA group showed a better VAS score at all follow-up moments (p < 0.01 for all), but no differences were found between both groups at all time points for other outcome measures. None of the HemiCAP® PFC implants needed to be revised within the timeframe of the study.
In this retrospective cohort study, we found a 100% survivorship of the HemiCAP® PFC implant at an average eight-year follow-up. However, no clinical benefits were found in performing trochlear resurfacing in conjunction with medial UKA for asymptomatic end-stage trochlear cartilage lesions. Therefore, these lesions can be safely ignored when performing a medial UKA.